Group 1: Financial Performance - In 2024, the company achieved operating revenue of 68,247 million yuan, an increase of 7.39% compared to the previous year [5] - The net profit attributable to shareholders was 5,212 million yuan, a decrease of 15.36% year-on-year [5] - The decline in profit is attributed to a weak market demand and falling prices in the magnesium industry [8] Group 2: Strategic Focus and Development - The company aims for steady development in 2025, focusing on enhancing production efficiency and implementing standardized management [5] - Key initiatives include tailings re-selection to drive sales growth and ensuring that fundraising projects are completed on schedule [5] - The company is committed to activating resources and improving project management to achieve new breakthroughs in production and sales [5] Group 3: Acquisition and Market Position - The company has paid a prepayment of 30 million yuan for the acquisition of 60% of Anshan Fuyou Mining Sales Co., Ltd., with the audit and evaluation process ongoing [6] - The acquisition of assets from "Hunterly" (Haicheng) Magnesium Mine is in the process of property transfer [9] - The company maintains a complete industrial chain in the magnesium resource sector, integrating R&D, mining, processing, and sales [11] Group 4: Industry Outlook - The magnesium industry is facing challenges due to a contraction in the steel industry and weak downstream demand, leading to a decline in overall market conditions [11] - The company’s performance in 2024 aligns with industry trends, with sales growth offset by price declines impacting profitability [11]

Group 1: Financial Performance - In Q1 2025, the company achieved a revenue of 75.51 million yuan, representing a year-on-year growth of 8.66% [5] - The net profit attributable to shareholders was 5.06 million yuan, with a year-on-year increase of 10.43% [5] Group 2: Industry Trends - The medical instruments and equipment manufacturing industry is experiencing steady growth, driven by continuous demand for low-temperature storage in life sciences and biopharmaceuticals [6] - The industry is shifting towards automation and intelligence, with government policies supporting domestic substitution and innovation in high-end medical devices [6] Group 3: Production Capacity and Investment Projects - The company operates four main production lines, including ultra-low temperature products and centrifuges, and has established additional production lines for various medical storage solutions [8] - Fundraising has been allocated to four projects: medical storage equipment, high-end medical devices, R&D center, and sales channel construction, with the sales channel project completed by the end of 2024 [8] Group 4: Strategic Business Planning - The company focuses on creating value for users and enhancing operational capabilities, with a strategy centered on deepening sample library ecosystems and expanding laboratory equipment offerings [9] - Continuous innovation and quality upgrades of existing products are prioritized, alongside the development of comprehensive solutions to facilitate technology transfer [9]

证券代码：920088 证券简称：科力股份 公告编号：2025-034 新疆科力新技术发展股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 投资者关系活动类别 □特定对象调研 □业绩说明会 □媒体采访 □现场参观 □新闻发布会 □分析师会议 □路演活动 √其他 （"2025 年新疆上市公司投资者网上集体接待日活动"） 上市公司接待人员：公司董事长兼总经理赵波先生；公司财务总监马红梅女 士；公司董事会秘书宋小青女士；公司证券事务代表张英丽女士。 三、 投资者关系活动主要内容 本次活动投资者提出的主要问题及公司对问题的回复情况如下： 问题 1：公司在 2024 年是否有新的产品或服务推出，市场反响如何？ 回答：感谢您的关注！公司持续进行技术创新和产品升级，2024 年，公司 获授权发明专利 3 项，实用新型专利 4 项，申请发明专利 3 项，实用新型专利 6 项。公司业绩稳中有升，市场稳定，谢谢! 问题 2：2024 年公司是否有新的生产基地或设施投入使用，对业务有何 ...

Company Overview - Shenzhen Longte Intelligent Control Co., Ltd. is identified by stock code 300916 and stock abbreviation Longte Intelligent [1] Financial Performance - Revenue growth in the first two quarters of 2024 was strong, but a decline is expected in the second half, primarily due to the consumer electronics PCBA segment [2] - The overall gross margin for 2023 and 2024 is approximately 17%, a decrease from previous years, mainly due to changes in product structure [2][3] - The gross margin for consumer electronics PCBA is around 12%, which negatively impacts the overall gross margin [2][3] Market Dynamics - The smart home appliance PCBA segment saw a revenue decline of 2.57% in 2024, attributed to intense price competition [4] - Competitors have shifted focus to mid-tier customers, increasing competition in the home appliance sector [5] Automotive Electronics - Major OEM clients include leading domestic car manufacturers and well-known companies in niche markets [6] - ODM projects are growing annually, with delivery cycles typically ranging from 6 to 12 months [7] - Key product lines in ODM include electronic oil pump controllers and electronic water pump controllers, each with varying market values [8] Future Outlook - The gross margin for automotive electronics is expected to improve in 2024 due to participation in high-end vehicle projects [9] - The subsidiary Longteng Future is in the incubation phase, with revenue targets to be adjusted based on project progress and market feedback [9] Product Performance - Revenue from new consumer electronics products is projected to be over 100 million, reflecting an 18.2% year-on-year decline due to reduced demand for niche products like pool robots [10] - The storage product segment experienced significant fluctuations, with a sharp increase in 2022 followed by a decline in 2023 due to changes in local energy subsidy policies [10] International Operations - Overseas direct sales accounted for approximately 30% of total revenue in 2024, with the U.S. market contributing about 4% of this total [10] - A new factory in Thailand is set to begin production in June, focusing on PCBA and finished products, with specific output values to be determined based on market demand [10] Strategic Planning - The company is currently focused on the first phase of the Thailand project and will evaluate further overseas expansion based on production performance and market conditions [10]

Group 1: Company Overview - AVIC Xi'an Aircraft Industry Group Co., Ltd. (AVIC Xifei) was established on June 18, 1997, and listed on the Shenzhen Stock Exchange on June 26, 1997, becoming the first listed company in China's aviation manufacturing industry [2][3] - The company primarily engages in the research, production, maintenance, and service of large and medium-sized aircraft and aviation components, collaborating with major international and domestic aviation companies like Airbus and Boeing [2][3] Group 2: Technological Development - The company emphasizes systematic development and actively expands into new technology fields, enhancing its product range and production delivery capabilities [3] - AVIC Xifei is committed to advancing information technology, digitalization, and intelligent manufacturing in the aviation industry, with a focus on upgrading production lines through new technologies [3] - The company has integrated artificial intelligence into its manufacturing processes, with notable achievements recognized by the Ministry of Industry and Information Technology [3] Group 3: Future Growth Prospects - Over the next five years, the company aims to focus on aircraft development, production, maintenance, and services, enhancing technological innovation and expanding subcontracting operations [4] - The company plans to improve its aviation maintenance service capabilities, offering integrated services that include maintenance, modification, and supply chain management [4] Group 4: Military Industry Opportunities - Recent conflicts, such as those between Pakistan and India, have highlighted the performance of China's aviation equipment, increasing the demand for modernization in national defense [5] - As a core enterprise in aviation equipment manufacturing, AVIC Xifei is positioned to respond to customer needs and enhance the reliability and applicability of its products, contributing to the development of China's military capabilities [5] Group 5: Innovation and Research - The company is advancing the "Large Aircraft Innovation Base" initiative, establishing high-level innovation platforms to support major project applications in aviation technology [5] - AVIC Xifei aims to create a collaborative innovation environment that fosters technological independence and contributes significantly to the advancement of aviation technology [5]

Group 1: Semiconductor Optical Business - The company's semiconductor optical business revenue for 2024 is approximately 17.7 million yuan, with ongoing efforts to expand customer cooperation and enhance technical exchanges [1][2] - The semiconductor optical business includes applications in lithography, packaging testing, and measurement, focusing on both mature and advanced processes [2] Group 2: Precision Processing Equipment - The company has invested in advanced processing equipment such as ion beam and magnetorheological polishing to meet high precision requirements in semiconductor and aerospace applications [3] - The advanced manufacturing process center has been established to enhance precision processing capabilities, although current utilization rates of these advanced machines are low due to product size differences [3] Group 3: Talent Development - As of the end of 2024, the company has over 700 employees, with 151 technical personnel, accounting for 21.09% of the total workforce [4] - The company plans to continue building a talent pipeline to enhance personnel quality and develop a high-caliber talent team [4] Group 4: Micro-Nano Optical Laboratory - The micro-nano optical laboratory has completed its main construction and is focusing on developing sub-wavelength optical components for various applications, including semiconductor optics and AR/VR [5] - The laboratory aims to collaborate with external universities and research institutions to enhance its R&D capabilities [5] Group 5: International Business and Trade Impact - In 2024, the company's overseas business generated revenue of 12,750.37 million yuan, accounting for 30.66% of total revenue, primarily from its wholly-owned subsidiary in Singapore [6] - The company is monitoring international trade environments and tariff policy changes to mitigate potential impacts on its business [6] Group 6: Profit Margin Outlook - The company's gross margin has declined due to lower margins on infrared optical products influenced by raw material supply issues [7][8] - The company continues to focus on high-value-added products in the industrial sector to maintain relative stability in gross margins [8]

Group 1: HVLS Fan Business - HVLS fan is the main business of the company, achieving revenue of 244 million yuan in 2024 with a gross margin of 36.95% [2] - The company holds a leading position in the domestic HVLS fan industry and has competitive products in the international market [2] - In 2024, overseas revenue accounted for 23.31%, indicating potential for further market expansion [2] Group 2: AI Business Development - The company is advancing AI applications through its joint venture, Henan Yuzhi Kaile Intelligent Technology Co., focusing on smart office, smart travel, and smart healthcare [2][3] - The AI solutions provided include private cloud deployment and customized AI application model development, ensuring data security and compliance [3] Group 3: Smart Driving Initiatives - A cooperation agreement was signed with the Henan Automotive Industry Investment Group to promote digital and intelligent upgrades in the automotive sector [4] - The collaboration aims to develop technologies related to autonomous driving, including unmanned vehicles for transportation and logistics [4] Group 4: Smart Government Solutions - In April 2025, a joint launch of the "Deep Language Future" smart government all-in-one machine was announced, in collaboration with People's Daily Online [5] - The all-in-one machine supports localized deployment and ensures data security through encryption and permission management [7] Group 5: AI Medical Solutions - The AI medical sector focuses on providing various AI solutions for different medical applications, including smart hospital renovations and AI imaging model validation [6] - Collaborations have been established with several top-tier hospitals for research projects, aiming to enhance clinical, teaching, and research capabilities through AI and big data [6]

Group 1: Business Performance and Revenue - The company has been operating its fresh meat sales business for one year, and its revenue for 2025 will depend on the business development and relevant regulations from the Shenzhen Stock Exchange [2] - The company aims to ensure over 100 million in revenue for 2025 through its beef sales, focusing on optimizing resource allocation and enhancing operational efficiency [3] - The company has temporarily reduced its live cattle breeding business due to financial constraints, impacting monthly sales volume [5] Group 2: Financial Management and Funding - To alleviate liquidity issues, the company is enhancing communication with financial institutions to secure financing support and has extended some one-year loans to three years [5] - The company has signed supplementary agreements with related parties to extend loans due by December 31, 2024, to the end of 2025 [5] - Measures to improve cash flow include reducing the scale of loss-making businesses, enhancing the profitability of quality assets, and increasing the efficiency of fund utilization [5] Group 3: Stakeholder Communication and Legal Matters - The company is committed to timely information disclosure regarding the progress of legal matters related to major shareholder bankruptcy and share auction [4] - The company is actively communicating with relevant departments regarding the execution progress of a complex criminal case involving share pledges [4]

Group 1: Real Estate Market Insights - The company actively responds to policies regarding special bonds for purchasing real estate, collaborating closely with local governments on land storage matters [3] - The real estate market shows signs of recovery, with new home sales in key cities experiencing year-on-year growth in Q4 last year and Q1 this year [3] - In March, the company successfully acquired approximately 27 acres of land in a core area of Chongqing, enhancing its resource portfolio [3] Group 2: Market Value Management - The company emphasizes market value management, implementing measures such as share buybacks and stakeholder engagement to boost market confidence [5] - A structured management mechanism for market value, including a "Market Value Management System" and "Valuation Enhancement Plan," has been established [5] - Future efforts will focus on transparent operations and enhancing business quality to reflect true corporate value in the capital market [5] Group 3: Debt Management - The company primarily relies on medium to long-term bank loans for its existing debt and adheres to a strict "631" risk management principle to ensure timely debt repayment [5] Group 4: Cultural and Tourism Business Development - The cultural and tourism sector is a core business area, with the company responding to national policies aimed at boosting consumption through various initiatives [6] - The company is innovating its operational strategies, focusing on enhancing existing projects and developing new products to capture market opportunities [6] - The company plans to upgrade existing theme parks and hotels, aiming to improve competitiveness and attract a broader customer base [6] Group 5: Asset Optimization Strategies - The company employs various asset optimization methods, including regulatory adjustments, inventory acquisition, and customized sales strategies [7] - A long-term mechanism for asset revitalization has been established, involving regular reporting and leadership oversight to ensure project progress [7]

Group 1: Product Development and Clinical Trials - The innovative drug Anglavei (brand name: Anruiwei®) has been approved for market release, showing significant efficacy in clinical trials compared to placebo, with a median symptom relief time of 38.83 hours versus 63.35 hours for the placebo group (P<0.001) [5] - Anglavei has demonstrated superior antiviral activity against various strains of influenza, outperforming existing treatments like Oseltamivir and Baloxavir, particularly against resistant strains [4] - The Phase II clinical trial for Anglavei granules in children aged 2-17 showed a median symptom relief time of 31.72 hours, with high-dose and low-dose groups showing times of 28.63 hours and 33.65 hours, respectively [4] Group 2: Safety and Efficacy - No serious adverse events were reported during the clinical trials of Anglavei granules, indicating good safety and tolerability in children and adolescents [7] - The Phase II trial results for Anglavei granules indicated that most adverse reactions were mild and resolved without treatment, confirming the drug's favorable safety profile [7] Group 3: Financial and Asset Management - In 2024, the company recorded an asset impairment loss of CNY 546.68 million, impacting the net profit attributable to shareholders by CNY 484.10 million [10] - The company has taken a cautious approach to asset management, including impairment provisions for inventory and goodwill, totaling CNY 201.68 million for goodwill impairment [10] Group 4: Strategic Initiatives and Market Positioning - The company plans to enhance its marketing strategy for Anglavei by building an academic ecosystem and integrating digital services to improve healthcare solutions [7] - The company has increased its stake in its subsidiary, Zhongsheng Ruichuang, from 61.11% to 74.26% by redeeming shares for CNY 546 million, strengthening control over its innovative drug development [29] Group 5: Research and Development Pipeline - The company has established a robust R&D ecosystem focusing on metabolic and respiratory diseases, with multiple innovative drug projects in various stages of clinical trials [13] - The innovative drug ZSP1601 for treating non-alcoholic steatohepatitis (NASH) has shown promising results in Phase II trials, significantly reducing liver inflammation markers [17] Group 6: New Drug Approvals and Market Impact - The oral antiviral drug Liratewei (brand name: Leruoling®) received conditional approval in March 2023 and is included in the national medical insurance directory, expanding access for patients [14] - RAY1225, a GLP-1 receptor agonist, has shown significant weight loss and glycemic control in Phase II trials, with a notable reduction in HbA1c levels [20]